<DOC>
	<DOCNO>NCT00401674</DOCNO>
	<brief_summary>The purpose study evaluate toxicity activity weekly administration carboplatin paclitaxel first-line chemotherapy elderly patient ovarian cancer stage IC-IV .</brief_summary>
	<brief_title>MITO-5 : Weekly Carboplatin Paclitaxel First Line Chemotherapy Elderly Patients With Ovarian Cancer</brief_title>
	<detailed_description>This phase II multicenter study . The experimental treatment carboplatin ( AUC 2 ) paclitaxel 60 mg/m2 , day 1 , 8 15 every 28 day .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Age 70 year great Cytologic / histologic diagnosis ovarian cancer Stage disease diagnosis IC IV Performance status ( ECOG ) &lt; 3 Indication chemotherapy treatment Written inform consent Previous concomitant malignant neoplasia ( include basocellular spinocellular skin carcinoma insitu carcinoma uterine cervix , provide adequately treat ) Cerebral metastases Neutrophils &lt; 1000/mm3 , platelet &lt; 100000/mm3 , hemoglobin &lt; 8g/dl Creatinine &gt; = 1.25 time upper normal limit GOT GPT &gt; = 1.25 time upper normal limit , except case liver metastasis ) Patient 's inability comply followup</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>elderly</keyword>
	<keyword>weekly chemotherapy</keyword>
	<keyword>first-line</keyword>
</DOC>